Navigation Links
Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event

Recent clinical studies support the development of DG041 as an effective anti-platelet that does not increase bleeding risk

REYKJAVIK, Iceland, June 25, 2007 /PRNewswire-FirstCall/ -- deCODE genetics today announced progress in the development of DG041, the company's Phase II developmental compound for the prevention of arterial thrombosis. The results of the Phase IIa and clinical pharmacology studies presented today build upon previous findings demonstrating DG041's profile as an anti-platelet compound that deCODE expects will make it possible to block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk. There is a large unmet medical need for a drug with these characteristics, with applicability to the prevention of heart attack, stroke and the progression of peripheral artery disease (PAD). Drugs such as Plavix(TM) and aspirin, the current mainstays of oral anti-platelet therapy, significantly increase the risk of bleeding by broadly blocking platelet activity.

Recent advances in deCODE's therapeutic and diagnostics pipeline will be discussed at the company's annual R&D event being held today in Reykjavik. The presentations will be webcast live through the investors page of the company's website at http://www.decode.com, starting at 9am GMT/5am EDT, and will be archived on the site. Among the highlights to be discussed are:

DG041 -- Arterial thrombosis.

DG041 is a novel, first in class antagonist of the EP3 receptor for prostaglandins E2. deCODE initially identified EP3 as a target by isolating variants in the gene encoding the EP3 receptor for prostaglandins E2 (PGE2) that approximately double the risk of PAD, a common and debilitating atherosclerotic condition in which the flow of blood to the legs is progressively constricted. The mechanism through which EP3
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:9/15/2014)... 2014  Decision Resources Group,s new Manhattan ... that online information and other value-added services ... their offering and support physicians. Physicians who ... rely on websites, mobile apps and other ... physicians are looking to manufacturers to provide ...
(Date:9/15/2014)... -- The Society of Corporate Compliance and Ethics ... 4,500 compliance and ethics professionals from across industry, ... fines and settlements.  The SCALENDAR is designed to ... reference to demonstrate to employees the consequences of ... help compliance and ethics officers looking for a ...
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... for In Vitro Diagnostic Tests, 9th Edition" report to ... entirety of the clinical testing market and all of its ... by Top IVD Companies For Business Planning. This ... the market events of 2013 and early 2014. New entrants, ...
Breaking Medicine Technology:Physician device decision-makers show strong demand for device manufacturer digital content and support 2Physician device decision-makers show strong demand for device manufacturer digital content and support 3More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 2The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition 3
... Goodrich Corporation (NYSE: GR ) at next ... real-time information to air crews and lower operating costs ... Heli-Expo 2011 takes place at the Orange County Convention ... Goodrich (booth 2142) will display its HUMS (Health ...
... Therapeutics Inc. (TSX: NPC), today announced that Gordon C. ... , March 3rd, 2011TIME: , 3:00 PM ESTLINK: ... online event where investors are invited to ask the ... as well as the company,s "virtual trade booth." If ...
Cached Medicine Technology:Goodrich to Showcase Advanced Helicopter Systems at Heli-Expo 2Allon Therapeutics to Present Live, Online at RetailInvestorConferences.com on March 3rd 2Allon Therapeutics to Present Live, Online at RetailInvestorConferences.com on March 3rd 3
(Date:9/15/2014)... September 15, 2014 Imaging can be ... stroke who might benefit from aggressive intervention, according to ... Radiology. , The study looked at people with ... blood vessels supplying blood to the head due to ... primary cause of up to 20 percent of ischemic ...
(Date:9/15/2014)... Calif. (PRWEB) September 16, 2014 Authors Christine ... through a compelling story of four alcoholics. Born out of ... to others, “ A Night In The Life... ” (published ... help those who are suffering from the same fate. ... Alcoholism is rampant in this. This book chronicles ...
(Date:9/15/2014)... at the University of Copenhagen have gained new ... disease. The findings have recently been published in ... , The defining symptoms of Parkinson,s disease are ... currently no cure for the condition, so it ... potential to shed some light on this terrible ...
(Date:9/15/2014)... DISCcert, a San Diego based DISC ... Certification Workshop for Oct 16th and 17th. Corporate ... take part in the intensive and highly regarded workshop. ... that can be immediately implemented into their business environment. ... educate employees and staff in DISC skills. Learning Activities, ...
(Date:9/15/2014)... Today, Zane Benefits, the #1 Online Health ... Business radio show. , According to Zane Benefits, ... it doesn’t make sense to choose a “one size ... employer and employee as much as 60 percent on ... Bank's Speaking on Business , Chris Redgrave, highlights the ...
Breaking Medicine News(10 mins):Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 2Health News:RSNA: Imaging Identifies Asymptomatic People at Risk for Stroke 3Health News:Authors show perils of alcohol abuse in new graphic novel 2Health News:Authors show perils of alcohol abuse in new graphic novel 3Health News:Researchers debunk myth about Parkinson's disease 2Health News:DISCcert Announces Two-day DISC Certification Workshop Oct 16 and 17 2Health News:DISCcert Announces Two-day DISC Certification Workshop Oct 16 and 17 3Health News:Zane Benefits Featured on Zions Bank Speaking on Business 2
... acquire the pharmaceutical Antifoam (Simethicone) business from Bluestar Silicones. ... ... 2009 -- NuSil Technology ( http://www.nusil.com ), a leading formulator ... industries, announced a definitive agreement to acquire the pharmaceutical Antifoam ...
... Type 1 diabetes is the most common chronic childhood ... includes regular fingerstick glucose measurements, multiple daily injections of ... spend a great deal of their time in school, ... Some researchers believe that the use of telecommunication ...
... May 20 The following is a statement ... Kids:(Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The ... Kennedy (D-MA) for his leadership in introducing and ... Drug Administration (FDA) regulatory authority over tobacco products, ...
... New Absence Management Portal Will Offer Innovative Predictive Disability Durations Tool ... ... Reed Group Ltd., the world,s most trusted provider of return-to-work information ... edition of its popular Medical Disability Advisor is now ...
... Alan B. Miller to Retain Chairman and CEO Positions Michael ... Pa., May 20 The Board of Directors of Universal ... nation,s largest hospital companies, today announced the election of Marc ... of Universal Health Service,s Chairman and Chief Executive, Alan Miller, ...
... outstate Minnesota MINNEAPOLIS, May 20 Today ClearWay ... dedicated to reducing tobacco,s harm through coalition building, ... provide resources to communities outside the Twin Cities ... commitment to reducing tobacco,s harm and educate all ...
Cached Medicine News:Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 2Health News:NuSil Technology Acquires Pharmaceutical Antifoam (Simethicone) Business from Bluestar Silicones 3Health News:Telemedicine may improve care for school children with diabetes 2Health News:Sen. Edward Kennedy Leads Fight to Protect America's Kids From Tobacco 2Health News:Reed Group Launches New MDGuidelines Web Site with 6th Edition of Medical Disability Advisor 2Health News:Reed Group Launches New MDGuidelines Web Site with 6th Edition of Medical Disability Advisor 3Health News:Universal Health Services, Inc. Announces Marc D. Miller Named President of Universal Health Services 2Health News:ClearWay Minnesota(SM) Board Approves Four Regional Grants 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: